Lv1
70 积分 2021-11-19 加入
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB–IIIB NSCLC
13小时前
待确认
Osimertinib in Stage III EGFR -Mutated NSCLC — Game, Set, Match
4个月前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
4个月前
已完结
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
4个月前
已完结
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
4个月前
已完结
New Sight of Renal Toxicity Caused by UV‐Aged Polystyrene Nanoplastics: Induced Ferroptosis via Adsorption of Transferrin
4个月前
已完结
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
5个月前
已完结
Patient-Focused Drug Development
6个月前
已完结
Increased Tumor Mutation Burden Levels and Sensitivity of Non–Small Cell Lung Cancer to PD-L1 Blockade
6个月前
已完结
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
8个月前
已完结
皖公网安备34019202002308
